Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Dolomite Bio's Single Cell RNA-Seq System accelerating cancer researchBy: Dolomite Bio "Initially I was using FACS to perform manual sorting of cells into individual wells, but this is both time consuming and laborious, limiting me to a maximum of 20 cells per experiment. As throughput is crucial in biomarker discovery, we wanted to perform our investigations on a much larger scale and, following the publication by Macosko et al1, we decided that microfluidics was the way forward. After a demonstration of the system at Dolomite Bio's headquarters near Cambridge, we chose the Single Cell RNA-Seq System, and can now run over 1,000 cells per experiment. Although we have only just finished optimizing our protocols, the throughput is very impressive and the system offers good reproducibility. The beauty of this technique is that it allows you to view many cellular events simultaneously and, once optimized, it's more cost effective than manually sorting and sequencing cells." For more information, visit www.dolomite- Disclaimer: The views stated are that of the individual, and not The Institute of Cancer Research 1 Macosko E et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161(5), 1202-14. About Dolomite Bio Dolomite Bio creates innovative products for high throughput single cell research. By encapsulating single cells in microfluidic droplets, our products enable rapid analysis of thousands or millions of individual cells and their biological products. Dolomite Bio is a brand of Blacktrace Holdings Ltd (www.blacktrace.com) Dolomite Bio's products include μEncapsulator System and RNA Seq system, suitable for use in many applications such as isolating antibody coding sequencing, profiling T cell receptors, droplets for FACS-sorting libraries and encapsulating cells in gel microbeads. To find out more about Dolomite Bio, please visit www.dolomite- End
Account Email Address Disclaimer Report Abuse
|
|